Press release
Age-related Macular Degeneration Market Size was approximately USD 9,840 Million in 2021
Age-related Macular Degeneration Market
Age-related Macular Degeneration Market is expected to gain market growth in the forecast period of 2022 to 2032. The growing cases of tumors will directly impact the growth of the Age-related Macular Degeneration market
The Age-related Macular Degeneration Market Insights report from DelveInsight provides a thorough understanding of current therapeutic approaches, emerging medications, Age-related Macular Degeneration market share of particular therapies, and current and projected market sizes from 2019 to 2032, divided into the 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Highlights from the Age-related Macular Degeneration Market Report
• The Age-related Macular Degeneration Market size is anticipated to increase during the study period, 2019-2032
• As per DelveInsight analysis, the Age-related macular degeneration market size in the 7MM was approximately USD 9.8 billion in 2021.
• As per DelveInsight estimation, the Dry AMD market size was approximately USD 1,377 million, and the Wet AMD market size was approximately USD 8,463 million, which is further expected to increase by 2032.
• Age-related Macular Degeneration Market Companies included such as Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics Inc., Unity Biotechnology Inc, PanOptica Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics and Novartis, Luxa Biotechnology, Gemini Therapeutics, and several others
Interested to know more about the ongoing developments in the Age-related Macular Degeneration Market Report? Visit here- Age-related Macular Degeneration Market Outlook- https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Age-related macular degeneration Overview
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries around the world, with a significant impact on the quality of life of the affected people. With the current expensive standard of care, the increase in Age-related macular degeneration life expectancy brings an increase in the number of reported cases, putting major stress on health care systems. Age-related macular degeneration (AMD) can also be characterized as either dry Age-related macular degeneration (atrophic or non-neovascular) or wet Age-related macular degeneration (exudative or neovascular).
Age-related Macular Degeneration Epidemiology Segmentation in the 7MM
• Total Age-related Macular Degeneration Prevalent Cases
• Total Age-related Macular Degeneration Diagnosed Prevalent Cases
• Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases
• Total Age-related Macular Degeneration Age-specific Cases
• Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by Stages
• Total Age-related Macular Degeneration Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment
Age-related Macular Degeneration Treatment Market
Photodynamic therapy, which employed an intravenous drug (injected into a vein) and laser to seal off bleeding blood vessels, was the best available Age-related macular degeneration treatment fifteen years ago. However, improvements in medical research have revealed VEGF as a critical pathophysiological factor in the development of neovascular AMD, with an important involvement in angiogenesis, vascular permeability, and inflammatory response. Anti-VEGF intravitreal injections have provided a new therapeutic window in the wet AMD treatment, effectively stopping the pathophysiological process of AMD and restoring retinal shape and function.
Discover more relevant information on the Age-related Macular Degeneration Market Research Report here- Age-related Macular Degeneration Market Size- https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Age-related Macular Degeneration Market Growth
The Age-related macular degeneration market growth is expected to boost owing to the expected launch of therapies, increasing prevalence of Age-related macular degeneration, development in the field of gene therapy, patient-friendly dosage regimes, and several other factors during the forecast period.
Age-related Macular Degeneration Therapeutics Market
The most common Age-related macular degeneration symptoms include blurry or fuzzy vision, loss of central vision, difficulty in recognizing familiar faces, and others. Visual acuity test, pupil dilation, fluorescein angiography, Amsler grid, and others are the following tests used for Age-related macular degeneration diagnosis.
Scope of the Age-related Macular Degeneration Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Age-related Macular Degeneration Market Companies- Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics Inc., Unity Biotechnology Inc, PanOptica Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics and Novartis, Luxa Biotechnology, Gemini Therapeutics, and several others
• Age-related macular degeneration Market Dynamics: Age-related macular degeneration Market Drivers and Barriers
Table of Content
1. Key Insights
2. Age-related Macular Degeneration Market Report Introduction
3. Age-related Macular Degeneration Market Overview at a Glance
4. Age-related Macular Degeneration Market Overview at a Glance
5. Age-related Macular Degeneration Market: Future Perspective
6. Age-related Macular Degeneration Executive Summary
7. Key Events
8. Disease Background and Overview
9. Age-related Macular Degeneration Epidemiology and Patient Population
10. Patient Journey
11. Age-related Macular Degeneration Marketed Drugs
12. Age-related Macular Degeneration Emerging Drugs
14. AMD: Seven Major Market Analysis
15. Key Opinion Leaders' Views
16. Age-related Macular Degeneration Market Drivers
17. Age-related Macular Degeneration Market Barriers
18. Age-related Macular Degeneration SWOT Analysis
19. Market Access and Reimbursement of Wet AMD
20. Age-related Macular Degeneration Unmet Needs
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Got Queries? Reach out for more information on the Age-related Macular Degeneration Market Research Report- https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Age-related Macular Degeneration Market Size was approximately USD 9,840 Million in 2021 here
News-ID: 3023278 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Poised for 7.1% Growth, Set to Hit …
How Are the key drivers contributing to the expansion of the macular edema and macular degeneration market?
The growth of the macular edema and macular degeneration market is predicted to be driven by the escalating number of individuals suffering from diabetes. Diabetes is a long-term health condition that results in elevated levels of glucose in the bloodstream. The condition harms the eye's blood vessels, potentially leading to macular edema and macular…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…
